APA (7th ed.) Citation

S, C., JY, B., IB, G., JS, d. B., C, L. T., V, M., . . . SA, P. (2022). Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. International journal of cancer, 150(6), 993. https://doi.org/10.1002/ijc.33861

Chicago Style (17th ed.) Citation

S, Cousin, et al. "Safety, Pharmacokinetic, Pharmacodynamic and Clinical Activity of Molibresib for the Treatment of Nuclear Protein in Testis Carcinoma and Other Cancers: Results of a Phase I/II Open-label, Dose Escalation Study." International Journal of Cancer 150, no. 6 (2022): 993. https://doi.org/10.1002/ijc.33861.

MLA (9th ed.) Citation

S, Cousin, et al. "Safety, Pharmacokinetic, Pharmacodynamic and Clinical Activity of Molibresib for the Treatment of Nuclear Protein in Testis Carcinoma and Other Cancers: Results of a Phase I/II Open-label, Dose Escalation Study." International Journal of Cancer, vol. 150, no. 6, 2022, p. 993, https://doi.org/10.1002/ijc.33861.